# A Study of VLX1570 and Dexamethasone in Myeloma Patients

> **NCT02372240** · PHASE1,PHASE2 · TERMINATED · sponsor: **Vivolux AB** · enrollment: 15 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** VLX1570 and dexamethasone

## Key facts

- **NCT ID:** NCT02372240
- **Lead sponsor:** Vivolux AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-08
- **Primary completion:** 2017-05-24
- **Final completion:** 2017-05-24
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Dose limiting tox is observed. Study put on full clinical hold.
- **Last updated:** 2018-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02372240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02372240, "A Study of VLX1570 and Dexamethasone in Myeloma Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02372240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*